Ally Bridge Group led the Series E round, while new investor Claret Capital Partners joined in. Existing investors also provided significant participation. That list includes Hostplus, M.H. Carnegie, Horizon 3 Healthcare, Lumira Ventures and a confidential strategic investor.

The company plans to use funds to complete a U.S. pivotal study and support the commercialization of its Carillon Mitral Contour System.

Kirkland, Washington–based Cardiac Dimensions designed Carillon to restore natural mitral valve function without damaging the mitral valve leaflets. The simple, catheter-based procedure restores the valve’s natural function and promotes favorable left ventricular remodeling.